Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors

作者：Liping Lin, Juanjuan Zhao, Ning Kong, Yan He, Jiazhu Hu, Fuxi Huang, Jianjun Han, Xiaolong Cao · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.18283 · 被引用次数：11 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Research Studies、Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

// Liping Lin 1, 4, * , Juanjuan Zhao 2, * , Ning Kong 3, 4 , Yan He 1, 4 , Jiazhu Hu 1, 4 , Fuxi Huang 1, 4 , Jianjun Han 1, 4 and Xiaolong Cao 1, 4 1 Department of Oncology, Panyu Central Hospital, Guangzhou, 511400, China 2 School of Nursing, Sun Yat-sen University, Guangzhou, 510000, China 3 Department of Ophthalmology, Panyu Central Hospital, Guangzhou, 511400, China 4 Cancer Institute of Panyu, Guangzhou, 511400, China * These authors contributed equally to this work Correspondence to: Liping Lin, email: linliping2017@tom.com Keywords: ALK-TKIs, interstitial lung disease, QTc prolongation, non-small-cell lung cancer, meta-analysis Received: April 16, 2017      Accepted: May 03, 2017      Published: May 29, 2017 ABSTRACT Background: To conduct a systematic review and meta-analysis to assess the overall incidence and risk of interstitial lung disease (ILD) and QTc prolongation associated with anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) in non-small-cell lung cancer (NSCLC) patients. Results: A total of 1,770 patients from 8 clinical trials were included. The incidences of high-grade ILD and QTc prolongation was 2.5% (95% CI 1.7-3.6%), and 2.8% (95% CI 1.8-4.3%), respectively. Meta-analysis demonstrated that the use of ALK-TKIs in NSCLC patients significantly increased the risk of developing high-grade ILD (Peto OR, 3.27, 95%CI: 1.18–9.08, p = 0.023) and QTc prolongation (Peto OR 7.51, 95% CI, ...